Benjamin Jaquish, MD
Vascular Surgery · Temple, TXNPI 1194027037
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (35.1%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Shockwave Medical, Inc accounts for 69.5% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $5,747, 5.2 times the $1,109 reported in 2019.
Across 52 payments — averaging $184.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shockwave Medical, Inc$7K
- Siemens Medical Solutions USA, Inc.$2K
- W. L. Gore & Associates, Inc.$621
- Medtronic$171
- Boston Scientific$146
- Solventum Corporation$129
- plus $91 from 2 others
What the payments were for
- Consulting fees$2,95031%
- Travel & lodging$3,27534%
- Food & beverage$3,36435%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shockwave Medical, Inc | 24 | $6,668 |
| Siemens Medical Solutions USA, Inc. | 13 | $1,763 |
| W. L. Gore & Associates, Inc. | 5 | $621 |
| Medtronic(2 entities) | 2 | $171 |
| Boston Scientific | 2 | $146 |
| Solventum Corporation | 1 | $129 |
| Lemaitre Vascular, Inc. | 3 | $52 |
| Abbott | 2 | $39 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,588 in reported general payments places this provider in the 55th percentile of 347 vascular surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 22 | $23,115 |
| EliquisApixaban | 20 | $21,274 |
| ClopidogrelClopidogrel Bisulfate | 20 | $370 |
| Gabapentin | 14 | $307 |
| Atorvastatin Calcium | 27 | $200 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 19 | $49 |
| Tramadol Hcl | 11 | $11 |
Paid to pharmacies, not to this prescriber.
Other vascular surgery in Temple
- Gregory PearlDallas$2.3M
- Mazin FotehAustin$1.6M
- Alan LumsdenHouston$742K
- Stephen HohmannDallas$499K
- Michael SiahDallas$392K
- Gustavo OderichHouston$319K
- Jean BismuthHouston$243K
- Carlos TimaranDallas$231K
- Dennis GableDallas$211K
- Thomas LohShenandoah$201K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.